Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 1093-1098

  Xiu, Mei Hong ^a   Chen, Da Chun ^a   Wang, Dong ^b   Zhang, Kui ^b   Dong, AiLing ^b   Tang, Wei ^c   Zhang, Feixue ^c   Liu, Lian Jing ^c   Liu, Jia Hong ^c   Liu, Hai Bo ^a   Yang, Fu De ^a   Kosten, Thomas R ^a,d   Zhang, Xiang Yang ^a,d  

^a PEKING UNIVERSITY   (China)

^b JingQu Hospital   (China)

^c Zhejiang Provincial Clinical Research Center for Mental Disorder   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Immune; Interleukin; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; INTERLEUKIN 18; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYMPTOM;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-18; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84863447379     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.026     Document Type: Article

References (44)

1. Alboni S., Cervia D., Sugama S., Conti B. Interleukin 18 in the CNS. Journal of Neuroinflammation 2010, 29:7-9.
2. Brown A.S., Susser E.S. In utero infection and adult schizophrenia. Mental Retardation and Developmental Disabilities Research Reviews 2002, 8:51-57.
3. Cannella B., Raine C.S. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Annals of Neurology 2004, 55:46-57.
4. Chengappa K.N., Ganguli R., Yang Z.W., Shurin G., Brar J.S., Rabin R.S. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biological Psychiatry 1995, 37:546-549.
5. Cumiskey D., Curran B.P., Herron C.E., O'Connor J.J. A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology 2007, 52(8):1616-1623.
6. Dinarello C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Seminars in Nephrology 2007, 27:98-114.
7. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. American Journal of Psychiatry 2006, 163:521-528.
8. Felderhoff-Mueser U., Schmidt O.I., Oberholzer A., Bührer C., Stahel P.F. IL-18: a key player in neuroinflammation and neurodegeneration?. Trends in Neurosciences 2005, 28:487-493.
9. Ganguli R., Brar J.S., Chengappa K.N., Yang Z.W., Nimgaonkar V.L., Rabin B.S. Autoimmunity in schizophrenia: a review of recent findings. Annals of Medicine 1993, 25:489-496.
10. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophrenia Research 1994, 14:15-22.
11. Katila H., Hurme M., Wahlbeck K., Appelberg B., Rimón R. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 1994, 301:20-23.
12. Kawashima I., Matsuoka Y., Fukuda J., Nohga K., Irimajiri S. A case of perforated appendix caused by secondary amyloidosis associated with rheumatoid arthritis. Nippon Shokakibyo Gakkai Zasshi 1996, 93:569-572.
13. Kawashima M., Ikeda H., Yorozu A., Niibe H., Teshima T., Fuwa N., et al. Clinical features of esophageal cancer in the octogenarian treated by definitive radiotherapy: a multi-institutional retrospective survey. Japanese Journal of Clinical Oncology 1998, 28:301-307.
14. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research 2000, 44(3):165-175.
15. Kim K.S., Pae C.U., Chae J.H., Bahk W.M., Jun T.Y., Kim D.J., et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Journal of Clinical Psychiatry 2002, 63:408-413.
16. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophrenia Bulletin 1993, 19:355-370.
17. Kohyama M., Saijyo K., Hayasida M., Yasugi T., Kurimoto M., Ohno T. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Japanese Journal of Cancer Research 1998, 89:1041-1046.
18. Kokai M., Kashiwamura S., Okamura H., Ohara K., Morita Y. Plasma interleukin-18 levels in patients with psychiatric disorders. Journal of Immunotherapy 2002, 25(Suppl.):68-71.
19. Kubota T., Fang J., Brown R.A., Krueger J.M. Interleukin-18 promotes sleep in rabbits and rats. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2001, 281(3):R828-R838.
20. Liu J., Liu J., Zhou Y., Li S., Li Y., Song X., et al. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA and Cell Biology 2011, 21:456-461.
21. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 1995, 29:141-152.
22. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophrenia Research 1996, 21:39-50.
23. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
24. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatrica Scandinavica 1993, 87:66-71.
25. Muller N., Reidel M., Ackenheil M., Schwarz M.J. The role of immune function in schizophrenia: an overview. European Archives of Psychiatry and Clinical Neuroscience 1999, 249(Suppl. 4):62-68.
26. Ossendorp F., M E., Camps M., Filius R., Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. Journal of Experimental Medicine 1998, 187:693-702.
27. Pariante C.M., Orrù M.G., Baita A., Farci M.G., Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999, 354:131-132.
28. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
29. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neuroscience 2011, 12:13.
30. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain, Behavior, and Immunity 2001, 15(4):319-339.
31. Schuld A., Hinze-Selch D., Pollmächer T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt 2004, 75(3):215-226.
32. Schwarz M.J., Müller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 2001, 56(4):483-486.
33. Shi F.D., Takeda K., Akira S., Sarvetnick N., Ljunggren H.G. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. Journal of Immunology 2000, 165:3099-3104.
34. Shirts B.H., Wood J., Yolken R.H., Nimgaonkar V.L. Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008, 147:343-350.
35. Smesny S., Rosburg T., Riemann S., Baur K., Rudolph N., Berger G., et al. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 2005, 72:393-402.
36. Smith R.S. A comprehensive macrophage T-lymphocyte theory of schizophrenia. Medical Hypotheses 1992, 39:248-257.
37. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Medical Hypotheses 1995, 45:135-141.
38. Sugama S., Conti B. Interleukin-18 and stress. Brain Research Reviews 2008, 58:85-95.
39. Sun S., Wei J., Li H., Jin S., Li P., Ju G., et al. A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population. Brain Research 2009, 1268:13-16.
40. Tanaka K.F., Shintani F., Fujii Y., Yagi G., Asai M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Research 2000, 96:75-80.
41. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry and Clinical Neurosciences 2010, 64(3):217-230.
42. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 2002, 57:247-258.
43. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Journal of Clinical Psychiatry 2004, 65(7):940-947.
44. Zorrilla E.P., Sanchez-Alavez M., Sugama S., Brennan M., Fernandez R., Bartfai T., et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(26):11097-11102.